bullish
Dr Reddy’s Laboratories - Decent Print; Work on Growth Levers Underway
Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment charge of gNuvaring (INR 924mn), was ahead of our expectations.
What is covered in the Full Insight:
- Introduction
- Q2FY25 Financial Performance
- Growth Drivers and Market Expansion
- R&D and Future Product Pipeline
- Valuation and Risks
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 19-minute read)
Discussions
(Paid Plans Only)
x